The FuSion Program: A Prospective and Multicenter Cohort Study of Pan-Cancer Screening in Chinese Population

Launched by SINGLERA GENOMICS INC. · Dec 2, 2021

Keywords

ClinConnect Summary

The FuSion Program is a research study aimed at improving how we detect cancer early in the Chinese population. The study will involve 10,000 participants who are healthy and will undergo annual physical exams over two years. Researchers are examining a special screening model developed by Fudan University and Singlera that combines various health data, including genetic information and tumor markers, to see how accurately it can identify potential cancers. After further refining this model with a larger group of 50,000 people over three years, its effectiveness will be tested in a real-world setting.

To be eligible for this study, participants must be adults who are healthy and have never been diagnosed with cancer. They will need to fill out a health questionnaire and undergo regular physical exams as part of the study. It’s important that participants can share any new health information related to cancer during the study and that they understand the study's purpose before giving their consent. This program not only aims to improve cancer detection but also encourages proactive health monitoring within the community.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Take physical examinations in our research centers and have no cancer history;
• • 2. "Population Health tracking Survey - simplified version of the questionnaire" must be filled according to the research program and an annual physical examination can be received as follow-up ;
• • 3. Timely feed back the information related to tumor diagnosis in other hospitals to the investigator during the program;
• • 4. Have no birth plan for the last 3 years;
• • 5. Fully understand the study and voluntarily sign the informed consent.
• Exclusion Criteria:
• • 1. Have been diagnosed with esophageal cancer, gastric cancer, colorectal cancer, liver cancer, lung cancer, pancreatic cancer, breast cancer (including non-primary, such as recurrence, metastasis or other complications) and other malignant tumors;
• • 2. Received blood transfusion, transplantation and other major operations within 3 months;
• • 3. Participated in other interventional clinical researchs within 3 months;
• • 4. Pregnant or lactating women;
• • 5. Patients with autoimmune diseases, genetic diseases, mental diseases/disabilities and other diseases considered unsuitable for the study by the investigator;
• • 6. Due to poor compliance, the researcher judged that the study could not be completed.